Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 33 of 36« First...1020...3132333435...Last »

Endo Pharmaceuticals Shells Out $130 Million for Nearly 70 Pipeline Programs From Aspen Pharmacare Holdings

DUBLIN — Endo International (ENDP) has continued its trend of expanding its portfolio through acquisitions, announcing a $130 million deal to acquire a large portfolio of anti-pain anti-infectives, cardiovascular and other therapeutics areas from Aspen Pharmacare Holdings, the company said this morning. The deal includes products that are currently on the market, as well as […]

Read More »

Horizon Pharma plc Announces Settlement of PENNSAID(R) 2% Patent Litigation With Perrigo Company plc

DUBLIN, IRELAND–(Marketwired – May 8, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Perrigo Company plc and its […]

Read More »

Prescription Fish Oil Maker Hires Top Lawyer To Sue FDA On First Amendment Grounds

Amarin Pharmaceuticals, which was rebuffed by the Food and Drug Administration in its effort to market its fish oil pill Vascepa to treat high triglycerides, is suing the agency, saying its First Amendment rights are being violated. To make its case, the small drugmaker has hired one of the nation’s top free speech lawyers, Floyd […]

Read More »

WHO adds hepatitis C drugs to essential list, urges lower prices

The World Health Organization has added new curative treatments for hepatitis C to its essential medicines list, but the U.N. agency said prices needed to fall to make them accessible to patients in poorer countries. The treatment of hepatitis C, which affects about 150 million people globally and kills around half a million each year, […]

Read More »

Novartis says lung cancer drug Zykadia gains EU approval

Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation. Zykadia, or ceritinib, is from a new class of medicines known as ALK inhibitors. It was approved in April 2014 in the United States. It is designed for use […]

Read More »

FDA staff say Vertex CF combo works, unclear how

Vertex Pharmaceuticals Inc’s combination of an experimental compound and an approved drug significantly improved lung function in cystic fibrosis patients with the most common genetic mutation underlying the disease, FDA staff said. The U.S. Food and Drug Administration staff reviewers, however, were not sure whether Vertex’s already approved therapy, Kalydeco, had a positive effect alone. […]

Read More »

It Costs $10K More To Treat People With Diabetes, Insurers Say

It now costs $10,000 or more per person annually to treat someone with diabetes than someone who doesn’t have the chronic disease, according to a new analysis of large insurance company claims data. The Health Care Cost Institute, a Washington-based group backed by some of the nation’s largest insurance companies including UnitedHealth Group (UNH), Humana […]

Read More »

EU patent office revokes Celgene Revlimid patent; appeal planned

(Reuters) – Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company’s flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine’s exclusivity in Europe. The so-called polymorph patent in question would have kept cheaper versions of Revlimid off the European market […]

Read More »

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

SAN DIEGO, May 7, 2015 /PRNewswire/ — Antiplatelet drug ticagrelor (Brilinta®) works faster and is more effective in blocking platelet activity in low-­risk patients with acute coronary syndrome (ACS) than clopidogrel, according to a new study presented today as a late-­breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San […]

Read More »

Novartis AG’s ‘biosimilar’ drug sale blocked by U.S. appeals court

(Reuters) – A U.S. appeals court has blocked the sale of Novartis AG’s recently approved “biosimilar” form of Neupogen, Amgen Inc’s blockbuster drug used to prevent infections in cancer patients. A lower court judge rejected Amgen’s request for an injunction. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the […]

Read More »

MarketResearch.com: Asthma Therapeutics Market to Reach $21.7 Billion by 2020, Says New GBI Research Report

WASHINGTON and NEW YORK and LONDON, May 7, 2015 /PRNewswire/ — As a leading provider of market research reports and solutions, MarketResearch.com is pleased to highlight a recent report by GBI Research, forecasting the asthma therapeutics market to hit $21.7 billion by 2020, a CAGR 2.4% over $18.4 billion in 2013. To view this report by […]

Read More »

J&J to consult ethicists on requests for experimental drugs

(Reuters) – Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on “compassionate use” requests, in which desperate patients ask drugmakers to let them take an experimental medication, the company announced on Thursday. The ethicists’ recommendations will be advisory, with J&J making the decision. But the drugmaker […]

Read More »

Venezuela says probing drugmakers for improper use of hard currency

(Reuters) – Venezuela is investigating whether drug companies including Germany’s Merck KGaA and Bayer AG have improperly profited from subsidized foreign exchange amid growing medicine shortages, the country’s health minister said. Those firms have received a favorable exchange rate through Venezuela’s currency controls to produce or import price-controlled medication to treat chronic ailments such as […]

Read More »

EU watchdog disagrees with negative view on UniQure gene therapy

(Reuters) – European regulators do not agree with the negative view expressed by one adviser about the efficacy of UniQure’s drug Glybera, the Western world’s first gene therapy. The Dutch company said it had received a final assessment report from the European Medicines Agency’s Committee for Advanced Therapies (CAT) following doubts raised by the adviser, […]

Read More »

Emergency Physicians Are Not Likely To Prescribe Opioids To Discharged Patients

While some people visit primary care physicians when they’re in pain, others head to the emergency room. With emergency physicians wanting to provide pain relief to their patients, prescribing opioids to discharged patients may seem like the best option to some — but many physicians are refusing to jump the gun too soon. Published in the Annals of Emergency Medicine, a journal […]

Read More »

Gilead’s John C. Martin: One Breakthrough Drug After Another

In his 25-year-tenure at Gilead, first as research chief and then as the boss, Martin led the development of the most widely prescribed HIV pill and, last year, a treatment for the liver virus hepatitis C that can cure 90% of patients and generated $12 billion in revenue in its first year on the market. It […]

Read More »

GSK sees little prospect of U.S. generic Advair in 2016

A logo of GlaxoSmithKline Pharmaceuticals Ltd company is pictured outside its headquarters in Mumbai December 16, 2013. Reuters/Danish Siddiqui (Reuters) – After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics – but not just yet. Chief Executive Andrew Witty said on […]

Read More »

Under pressure, FDA to hold public meeting on off-label use

(Reuters) – The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their First Amendment right to free speech. The meeting, announced last month by FDA chief counsel Elizabeth Dickinson, comes as a bill […]

Read More »

The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years

The global market for cancer drugs has hit $100 billion in annual sales, and could reach $147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics, a unit of drug data provider IMS Health. This figure does not include discounts or rebates paid to insurers and government programs; IMS […]

Read More »

Global cancer drug spending hits $100 billion in 2014: IMS Health

(Reuters) – Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health’s Global Oncology Trend Report released on Tuesday. The $100 billion, which represents 10.8 percent of all drug spending globally and includes supportive care drugs […]

Read More »

Page 33 of 36« First...1020...3132333435...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom